Ping An Securities: Maintains "Strong Buy" rating on YUYUE MEDICAL, optimistic about the company's sustained growth capability

Ping An Securities' research report pointed out that YUYUE MEDICAL achieved a net profit attributable to the parent company of 1.203 billion yuan in the first half of 2025, a year-on-year increase of 7.37%. In the second quarter alone, the company achieved a net profit attributable to the parent company of 578 million yuan, a year-on-year increase of 25.43%. The performance growth is in line with expectations, with outstanding performance in blood glucose AED and other businesses; overseas business is steadily advancing, becoming an important driver of performance growth. The company is gradually building an integrated health management ecosystem of "hardware + software + data," launching the YUYUE AIAgent application in the first half of 2025, providing an important interface to enhance user stickiness. The company is a leading enterprise in the domestic medical device industry, with significant product and quality advantages. The "YUYUE" brand is deeply rooted in people's hearts, with the scale of various product businesses continuously expanding, product categories constantly being developed, and the company's overall competitive ability and risk resistance significantly improving. Considering the company's continuously growing comprehensive strength, the continuous release of new products, and the rapid development of overseas business, we are optimistic about the company's sustained growth capability and maintain a "strong buy" rating